DNMT1 and Hyperglycemia: ApoE−/− mice with hyperglycaemia (DM) for 16 weeks followed by 6 weeks of normoglycaemia (NG, achieved by SGLT2 inhibitor treatment) and concomitant aPC treatment were injected with a DNMT1 specific morpholinos (DM-NG-aPC-DNMT1-MO) or a non-specific control morpholino (DM-NG-aPC-Cont-MO, Fig. 10a).